June 10, 2008 - Oral presentation on the potent blood glucose lowering effect of SGLT2 antisense inhibitors in multiple preclinical models - Eight additional presentations highlight significant activity in eight new metabolic disease targets utilizing antisense - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced the presentation of new preclinical data showing that antisense drugs potently reduce levels of sodium dependent glucose transporter type 2 (SGLT2), a key component in controlling glucose re-absorption in the kidney and the target of ISIS 388626. In addition, Isis presented results from eight research programs on novel targets that offer new mechanisms to treat metabolic diseases. The nine presentations (including two late-breaking abstracts) were presented during the American Diabetes Association's (ADA) 68th Scientific Sessions in San Francisco by Isis and its collaborators....
The presentation titled "Long Term Safety and Efficacy of ISIS 388626, an Optimized SGLT2 Antisense Inhibitor, in Multiple Diabetic and Euglycemic Species," showed that antisense reduction of SGLT2 produced the following results in preclinical models:
-- Lowered HbA1c, a measure of average blood glucose over time in
diabetic animals, and reduced fed and fasted blood glucose levels,
while also ameliorating diabetic complications, including slowing
progression of cataract formation.
-- Lowered SGLT2 mRNA levels in the kidney by approximately 80% in all
species tested, with doses as low as 1-2 mg/kg/week with no effect on
SGLT1, a related protein, where levels of activity is desirable.
-- Showed no changes in urinary or plasma markers of renal function and
no harmful effects such as low blood glucose.
... Isis Pharmaceuticals' Press Release -
